CDRH's Burlington on drug model
This article was originally published in The Gray Sheet
Executive SummaryFDA Center for Devices and Radiological Health Director Bruce Burlington pledges at "all hands" staff meeting March 3 that he is "not going to transfer the so-called 'drug model' from" the Center for Drug Evaluation and Research to the device center. Burlington added that he "is not going to be satisfied with halfway measures when it comes to scientific rigor in the device review process." Burlington was a CDER topsider before moving to CDRH Feb. 22 ("The Gray Sheet" Feb. 8, p. 1).
You may also be interested in...
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.
Consumer health product firms say the coronavirus will have an impact on their results, but it’s too early to estimate the costs. US FDA also hedges its predictions, saying the outbreak could lead to interruptions in country’s drug and medical device supplies. China's health commission has issued six guidelines for diagnosis and treatment, but no conventional antiviral treatment is approved and it's emphasizing traditional Chinese medicines.
With less than one hundred days left before the European Union Medical Device Regulations kick in, Medtech Insight’s executive editor Ashley Yeo and managing editor Amanda Maxwell discuss growing concerns by medtech industry members that they may not be ready in time to comply with these regulations and may inadvertently go afoul of the new regulations.